Show Notes:
This week we discuss:

• Pfizer’s medical education relationship with the Canadian Medical Association
• Journalists take FDA to task for not being transparent enough
• Layoffs and job cuts at Sanofi-Aventis
• New report shows that DTC receives more funding than sales calls in certain drug categories
• CEO compensation bump in life science

To subscribe add this feed to your favorite media player:

http://feeds.feedburner.com/pharmapodcast

Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special.

Eli Lilly: With double-digit growth in sales, and a solid improvement in revenue per employee, Lilly placed fourth in the Company of the Year rundown. Bill Trombetta explains Lilly’s position as a big/small pharma and maps out the challenges that lie ahead for Lilly.

What’s the best managed pharma? Each year, Professor Bill Trombetta of Saint Joseph’s University attempts to answer the question in Pharm Exec’s “Industry Audit”, applying a battery of traditional and nontraditional metrics to the largest publicly held companies.

This year, in addition to his article, Bill agreed to sit down with editor-in-chief Patrick Clinton for a conversation on the top four companies and what makes them special.

How to measure a pharma company If you want to want to truly understand how well a company is performing, you need to get past the basics of revenue, profit margin, and price earnings ratio. In this episode, Bill Trombetta explains which metrics really get at the heart of good pharma management.

To subscribe to the Pharm Exec Podcast series enter the following RSS feed into your favorite music player: http://feeds.feedburner.com/pharmexecpodcasts?format=xml